Bioverativ and Bicycle Therapeutics to develop new haemophilia and sickle cell disease treatments

US biotechnology company Bioverativ has entered a new research collaboration with UK-based Bicycle Therapeutics to discover, develop and commercialise new therapies for haemophilia and sickle cell disease.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news